Health & Biotech
PharmAust Limited (ASX:PAA) is a clinical-stage biotechnology company developing therapeutics for human and animal health applications.
The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs. MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).
PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently completing a Phase 1 study in patients with MND/ALS. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase 1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
PharmAust files groundbreaking MND/ALS clinical data with the FDA
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results
Health & Biotech
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
News
ASX February winners: The best 50 stocks as a ‘super-heroic small cap’ soars 322%
Health & Biotech
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Health & Biotech
PharmAust’s MPL could offer MND/ALS patients up to 56.5 months additional life expectancy
News
Closing Bell: The ASX has come a long way and gone nowhere on Monday
News
Hot Money Monday: This is what the Father of Momentum Investing thought about ‘undervalued’ stocks
News
ASX Small Caps and IPO Weekly Wrap: The week we learned what Woolies is really worth
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Thursday and the ASX200 is flat and porous. I am unhappy… But at least Bega made a lot of cheese
Health & Biotech
PharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALS
Health & Biotech
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again
News
Closing Bell: Material gains for the ASX on Friday while a good week at work sees Tech Sector gain 7.5pc
Health & Biotech
FDA shows the way for accelerated approval of PharmAust’s monepantel in MND
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech